Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.

NCT Number	NCT07358195
Lead Sponsor	Massachusetts General Hospital
Conditions	Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic Cancer
Enrollment	3 participants
Start Date	2026-07
Primary Completion	2028-12 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-01-22